The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence
To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
140
sugar pill manufactured to mimic cabergoline 05mg tablet
Torrance Clinic
Torrance, California, United States
Medical University of South Carolina
Charleston, South Carolina, United States
To assess the efficacy of cabergoline in reducing cocaine use in subjects with cocaine dependence
Success in the reduction of cocaine use was determined by comparing cocaine non-use days (self-report confirmed or disproved by urine BE level at each study visit) expressed as the weekly mean proportion of non-use days to the total number of non-missing study days that week.
Time frame: Week 12
Reduction in cocaine use
Measured by the weekly mean proportion of non-use days according to the subject's self report without regard to BE levels
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.